Biopure firm’s success is highly dependent on its decision to launch veterinary blood substitute Oxyglobin ahead of its human blood substitute, Hemopure. The main concern for Biopure is the negative effects of pricing Oxyglobin at $150-$200 on the Hemopure, which is to be priced between $600- $800. Since both products are identical in composition and as such, Oxyglobin is an ancillary product of Hemopure, Biopure will find it challenging to justify the high price of its Hemopure product. By launching Oxyglobin early Biopure can generate revenues and create its own market in the veterinary sector. With this success, Biopure can go public and become a valuable company. Moreover, per Andy wright, Biopure will get enough learning and can improve its product based on feedbacks. …show more content…
On the other hand, if Biopure chooses not to launch Oxyglobin then it will lose the revenue stream and an opportunity to differentiate itself in the market. Moreover, Biopure, with Hemopure, will be entering the market along with other two competitors and will face fierce competition. Additionally, Biopure competitors, Baxter International and Northfield Laboratories, are launching blood substitutes relied on human blood, Biopure will need to address the endowment and status quo effects and convince consumers to shift from using human based blood substitutes to cattle based blood substitutes and hence will lose valuable time to promote the benefits of its Hemopure product before launch. Finally, based on the analysis of gains and losses, it is recommended that Biopure to launch Oxyglobin because it has a relative advantage than not
Cynthia Adae was taken to Clinton Memorial Hospital on June 28, 2006. She was taken to the hospital with back and chest pain. A doctor concluded that she was at high risk for acute coronary syndrome. She was transferred to the Clinton Memorial hospital emergency room. She reported to have pain for two or three weeks and that the pain started in her back or her chest. The pain sometimes increased with heavy breathing and sometimes radiated down her left arm. Cynthia said she had a high fever of 103 to 104 degrees. When she was in the emergency room her temperature was 99.3, she had a heart rate of 140, but her blood
Payers are consolidating, providers are merging, and both are vertically integrating, creating a new breed of hybrid clinical and risk-bearing customers for Medtronic. Their struggle to effectively manage outcomes and costs exposes a need that Medtronic can address.
BioPure Corporation, which was founded in 1984 by entrepreneurs Carl Rausch and David Judelson, is a privately owned biopharmaceutical firm specializing in the ultra purification of proteins for human and veterinary use. In 1998 Biopure pioneered the development of oxygen therapeutics using “Hemoglobin”, a new class of pharmaceuticals that are intravenously administered to deliver oxygen to the body's tissues. Biopure's two products, Hemopure for human use, and Oxyglobin for animal veterinary use, both represented a new Oxygen based treatment approach for managing patients' oxygen requirements in a broad range of potential medical applications. The factor distinguishing Biopure’s two products from other blood substitute products being developed by two possible rivals, Baxter International and Northfeild Laboratories, is that its hemoglobin based source is bovine rather than human and was derived from the blood cells of cattle. Both of Biopure’s blood substitute products were in the final stages of the approval process of the Food and Drug Administration (FDA) in 1998. Oxyglobin had just received the FDA’s approval for commercial release declaring it safe and effective for medical use. Hemopure was entering final Phase 3 clinical trials and was optimistically expected to see final FDA approval for release in 1999. The FDA approval of Oxyglobin and its possible subsequent release into the veterinary market caused concern over whether the early release of Hemoglobin would impinge BioPure’s ability to price Hemopure when the product finally received approval. Given that the two products were almost identical in properties and function, it was thought that the early release of Oxyglobin would create an unrealistic price expectation for Hemopure if released first.
Nucleon is a small biotechnology start-up with a very promising potential product (CRP-1), which is also the first product that Nucleon is planning to go into the clinic market. Nucleon has reached to human clinical trials phase with its product and it has no manufacturing facilities that satisfy the guidelines for these clinical trials and testing. Nucleon is on the verge of making a critical choice of manufacturing strategy, which will affect Nucleon’s survival in the intense competition in the long haul. Nucleon management is aware of the facts that they have a limited budget to start with, the financial environment in biotechnology is rapidly changing and establishing the safety and efficacy of products like CRP-1 is complex, time-consuming and expensive; that’s why they want to evaluate risks and rewards of each manufacturing strategy before making their final decision.
Immar Medrano was employed as a journeyman electrician by Marshall Electrical Contracting, Inc. (MEC). Medrano attended an electrician apprenticeship night class at a community college. His tuition and books were paid for by MEC. One night, when Medrano was driving home from the class, a drunk driver crossed the centerline of U.S. Highway 65 and collided head-on with Medrano’s automobile. Medrano died in the accident. His wife and two children filed a workers’ compensation claim for death benefits against MEC. Medrano’s family should receive workers compensations since he was acting within the scope of his employment when he sustained injuries in the car crash that resulted in his death. This was in the scope of his employment since MEC paid
Julie Bate was a long-term employee before he involved in a serious car accident. Even Julie does not have outstanding work performance but she have 5 years work experiences.
In the review of the case file State v. McAlister the client Jose McAlister is advised to accept the guilty plea offer from the prosecution. The state is charging Jose McAlister with murder in the 2nd degree, with up to life imprisonment; possession of cocaine with the intent to distribute, with up to thirty years of incarceration; possession of child pornography, with up to two years incarceration; and possession of a firearm in furtherance of drug trafficking, with a mandatory consecutive sentence of five years’ incarceration. The prosecution conducted a plea offer to pleading guilty to possession of cocaine, with a sentence of eight years’ concurrent incarceration; possession of child pornography, with five years’ concurrent incarceration;
It is quite unfortunate that some of the largest of hospitals in the country had run out of stock and those who seek medical attention can only resolve to cheap options in the black market (Forero, 2015). The greatest danger with purchasing items from the black market leave alone medicine is that there is high probability of buying defective products. For example, buying medicine from black market is more risky and puts the lives of the patients at
Ms. Case is a 38 year old female who presented to the ED after wrecking her car late yesterday afternoon into a wall in a parking lot. Ms. Case Eloped from ED just prior to wrecking vehicle after refusing "headache cocktail". Ms. Case denies wanting to harm herself, she reports just having poor judgement during a anxiety attack. At the time of the assessment Ms. Case denies suicidal ideation, homicidal ideation and symptoms of psychosis. Ms. Case reports a history of PTSD, Anxiety, depression, and Schizo-affective Disorder. She reports yesterday attempting to park her car in a parking lot after experiencing an anxiety attack while driving. Ms. Case states, "I tried to slam on breaks, but I actually think I slammed on the gas." She further states, "I don't want to hurt myself." Ms. Case reports a history of multiple sexual assaults and rapes. She reports at the age of 17 she was molested by a neighbor, at the age of 24 she was sexually raped by "the east coast rapist", and another time by an unknown individual. Ms. Case reports she experiences flashback and frequently have nightmares. Ms. Case expresses symptoms of depression from these traumatic events. She expressed depressive symptoms as feelings of worthlessness, sadness, isolation, insomnia, and anger. She denies any current
Ann Hopkins was denied a partnership at Price Waterhouse Coopers (PwC), a prominent professional services networking firm based in the United States, in 1982 (Badaracco, 1). She later sued the company for discriminatory promotion practices due to her loss. While the Supreme Court ruled that Ann Hopkins was indeed discriminated against the promotion, there can be arguments made for and against the view that Ann Hopkins was subject to discrimination during the assessment process. The case can be made that Hopkins was discriminated against due to three key factors during the assessment. These factors, while independently may not necessarily denote discriminatory behavior, can still signify discriminatory conduct based on the context and weight
PER REPORTER: Pacey said Andaija reported to her allegations regarding her foster parent’s son (Jaquarius) making sexual advances towards her. According to Andaija, Jaquarius touched her on her breast, tried to get her to look at his private area, and grabbing her inappropriately trying to make her sit in his lap. Andaija said this situation has been going on since the second week of her being in the family’s home. Andaija said she reported the allegations to an adoption specialist; which resulted in the lady asking her if anyone in the home was hitting her and when she said no nothing was done about the situation. Pacey said she is not sure if there have ever been any witnesses around during the time of Jaquarius’s behavior towards Andjaija.
This week’s case study concerning Genzyme’s strategic direction was very interesting in that they essentially pursued a strategy that seemingly was purposely avoided by other players in the pharmaceutical industry (Schilling, N.D.). Their strategy centered on developing prescriptions for rare diseases. Typically “developing a drug takes 10 to 14 years and costs an average of $800 million to perform the research, run the clinical trials, get FDA approval, and bring a drug to market,” and in turn it is normally intuitive, from an economic standpoint, to attempt to develop drugs that will have a substantial market so to be able to assure enough revenue is generated to produce a significant profit. In turn, drugs marketed towards treating
In the case study Blood for Sale, Sol Levin, the founder of Plasma International, is seen participating in a highly controversial act: buying and selling blood for profit. In this paper, I will show the advantages and cons of taking part in commercial transactions in blood from the egoistic, the utilitarian, and the Kantian perspectives as well as my stand on the company’s actions.
1. Hematal's cash flow problem limits Hematal's decision on giving further credit to the boy's family or not. It has been proved in the case that the family is very poor and won't be able to pay right away and most probably won't be able to pay anymore considering also the increasing hospitalization bills. This fact is important because Hematal will already have to consider writing off of the family's debt, which further affects the company's cash position in the future when she gives additional credit. The boy needs at least 20 more vials yet, Hematal has less than 20 vials left on stock. With this fact, I have assumed that Dr. Rini's decision should be an "all or nothing" kind of decision because anything less will not make any difference in the boy's condition considering also the fact that he needed more than 40 vials during his initial surgery, thus I conclude that the boy will die if less than 20 vials were provided. Therefore, Hematal will have to order more vials from Gamma Corp. to fill the 20 vial requirement.
The first factor that one should consider is the cost of buying synthesizing medication versus taking the natural approach. According to Forbes Magazine consumers spent an estimated $3.5 billion on herbal supplements, almost twice the amount as in 1994. (Forbes 28) However Goldenseal now costs $100 a pound, up from $15 a pound a decade ago. When one considers the fact that it costs $1 billion, and requires 10 to 15 years of R&D to bring out a synthetic drug, one has to wonder why put up with it. The Rural Advancement Foundation International (RAFI), a small, non-profit organization, estimates that medicinal plants and microscopic organisms from the Third World contribute between US $30-60 billion a year to the US pharmaceutical industry alone.(Brace 14).